Paradigm Health just lit up the clinical research world with a Series B that did more than clear the bar. It bent it. The company raised $78M in an oversubscribed round led by ARCH Venture Partners, with DFJ Growth stepping in and the returning crew at F Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital and the American Cancer Society’s BrightEdge Fund leaning in with super pro rata energy. When investors start doubling their lane space instead of just defending it, you know the signal is real.
What makes this moment hit different is that Paradigm Health was never built as another tech outfit trying to accessorize healthcare. Robert Nelsen and ARCH incubated it with a simple but ruthless question. Why do less than 5% of cancer patients ever touch a trial when the science exists and the need is immediate? That question connected with the lived experience of CEO Kent Thoelke, who spent 30+ years inside global research at ICON and PRA watching human time get lost in administrative gravity. Put those two forces together and you get a company willing to rebuild the clinical research ecosystem the way it always should have worked.
Then Paradigm Health pulled a power move. The same day as the funding, it acquired Flatiron Health’s Clinical Research Business, pulling 25+ academic medical centers, nearly 100 community oncology practices and reach to 2.4M+ patients into one aligned network. With OncoEMR integrated directly into its AI-native infrastructure, Paradigm Health now anchors the largest oncology research network in the U.S., touching 70% of the nation’s cancer population across 45 states and 2,100 care locations. That is not expansion. That is gravitational pull.
The platform’s AI, powered by GPT-4 and domain specific models, screens patients with 10% higher accuracy and 90% less expert validation time, moving from 50 manual reviews a day to hundreds per minute. Trial enrollment climbs 4x faster on average, with some studies hitting 6.5x speed and 20–30% lower costs. When a community system like Altru jumps from 4% to 11% trial participation and doubles prescreening volume from 10,200 to 21,200 visits, access stops being an aspiration and becomes infrastructure.
Leaders like Jonathan Hirsch, Jay Trepanier, Elijah Meerson, Michelle Lee and Dr. Paul Kluetz are shaping a platform already trusted by 15 of the top 20 global biopharma sponsors. Paradigm Health is positioning itself as the connective layer research has been missing, and for sponsors, providers and patients, this moment is one to watch closely because the horizon just moved closer.
Startups Startup Funding Venture Capital Series B AI Biopharma Cancer Cancer Tech Healthcare Health Tech Infrastructure Technology Innovation Tech Ecosystem Startup Ecosystem
